ATE485039T1 - Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen - Google Patents

Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen

Info

Publication number
ATE485039T1
ATE485039T1 AT04710592T AT04710592T ATE485039T1 AT E485039 T1 ATE485039 T1 AT E485039T1 AT 04710592 T AT04710592 T AT 04710592T AT 04710592 T AT04710592 T AT 04710592T AT E485039 T1 ATE485039 T1 AT E485039T1
Authority
AT
Austria
Prior art keywords
treatment
artemisinin
methods
viral infections
tumors formed
Prior art date
Application number
AT04710592T
Other languages
English (en)
Inventor
Richard Schlegel
Dan-Paul Hartmann
Astrid Baege
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE485039T1 publication Critical patent/ATE485039T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT04710592T 2003-02-12 2004-02-12 Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen ATE485039T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44674303P 2003-02-12 2003-02-12
PCT/US2004/004067 WO2004071506A1 (en) 2003-02-12 2004-02-12 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections

Publications (1)

Publication Number Publication Date
ATE485039T1 true ATE485039T1 (de) 2010-11-15

Family

ID=32869550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04710592T ATE485039T1 (de) 2003-02-12 2004-02-12 Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen

Country Status (9)

Country Link
US (7) US7989491B2 (de)
EP (3) EP3257509A1 (de)
CN (2) CN103393672A (de)
AT (1) ATE485039T1 (de)
CA (1) CA2515761C (de)
DE (1) DE602004029651D1 (de)
ES (1) ES2353384T3 (de)
MX (1) MXPA05008527A (de)
WO (1) WO2004071506A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842719B2 (en) * 2002-10-31 2010-11-30 Kemin Foods, L.C. Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
DE602004029651D1 (de) * 2003-02-12 2010-12-02 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
US20110206636A1 (en) * 2003-09-16 2011-08-25 Kemin Foods, LLC Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
CN1311832C (zh) * 2005-01-12 2007-04-25 四川科伦药业股份有限公司 溴代二氢青蒿素的医药用途
WO2009155379A2 (en) * 2008-06-17 2009-12-23 Hhv-6 Foundation Artemisinin and derivatives thereof as antivirals
WO2010082219A2 (en) * 2009-01-14 2010-07-22 Lincoln Pharmaceuticals Limited An arteether injection for treatment of malaria
US20100279976A1 (en) * 2009-04-30 2010-11-04 Shanghai Institutes For Biological Sciences, Cas Use of artemisinin and its derivatives in cancer therapy
EP2289554A1 (de) * 2009-07-31 2011-03-02 Dafra Pharma N.V. Zusammensetzungen enthaltend Thalidomid und Artemisinin für die Krebsbehandlung
WO2011071981A2 (en) * 2009-12-08 2011-06-16 The Johns Hopkins University Anti-cytomegalovirus activity of artemisinin-derived dimers
TWI482621B (zh) * 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
PL2838903T3 (pl) 2012-04-18 2018-04-30 The Hong Kong University Of Science And Technology Sposoby i kompozycje do leczenia zakażeń wirusowych
CN102755316A (zh) * 2012-07-16 2012-10-31 中国科学院武汉病毒研究所 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用
JP6513576B2 (ja) * 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
FR3008695B1 (fr) 2013-07-16 2021-01-29 Corning Inc Verre aluminosilicate dont la composition est exempte de metaux alcalins, convenant comme substrat de plaques de cuisson pour chauffage a induction
US9918972B2 (en) * 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
CN104906558B (zh) * 2015-07-08 2016-11-16 广东天普生化医药股份有限公司 治疗宫颈癌的含有乌司他丁的药物组合物
GB201805665D0 (en) * 2018-04-05 2018-05-23 Univ Nottingham Antiviral Compounds And Methods
US20210196676A1 (en) * 2018-05-30 2021-07-01 The Board Of Regents Of The University Of Texas System Treatment of viral infections and virally associated lesions with sequiterpene lactones
CN110507819B (zh) * 2019-08-13 2021-02-19 华南农业大学 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用
WO2021186396A2 (en) * 2020-03-18 2021-09-23 Oncotelic Inc. Tgf-beta inhibition, agents and composition therefor
PL4129290T3 (pl) * 2020-03-26 2025-10-13 Shin Poong Pharmaceutical Co., Ltd. Kompozycja farmaceutyczna zawierająca pironarydynę lub jej sól, artemizyninę lub jej pochodną lub kombinację ich obu do zapobiegania lub leczenia choroby układu oddechowego wywołanej przez koronawirusa
US20230233520A1 (en) * 2020-04-23 2023-07-27 Georgetown University Combination therapy of artemisinin-related compounds and histone deacetylase inhibitors for treatment of hpv-related benign, premalignant, and malignant diseases
US20230263768A1 (en) * 2020-06-26 2023-08-24 Solstar Pharma Water-soluble artesunate-based therapy for coronavirus infection
CN112294795B (zh) * 2020-11-17 2022-03-29 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用
WO2023090947A1 (ko) * 2021-11-18 2023-05-25 주식회사 노브메타파마 코로나바이러스 감염 질환의 예방 또는 치료용 약제학적 조성물
WO2024192348A2 (en) * 2023-03-15 2024-09-19 Ohio State Innovation Foundation Methods of treating hpv in hiv-infected patients
WO2025193922A1 (en) * 2024-03-15 2025-09-18 Emory University Use of artificial intelligence derived features of collagen architecture to make medical prognosis in cancer patients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225554A (en) * 1986-12-18 1993-07-06 Sri International Polyoxa tetracyclic compounds
US4916204A (en) 1987-07-31 1990-04-10 Massachusetts Institute Of Technology Pure polyanhydride from dicarboxylic acid and coupling agent
US5219880A (en) * 1991-03-29 1993-06-15 Dermatologic Research Corporation Treatment of viral tumors and hemorrhoids with artemisinin and derivatives
CN1051451C (zh) 1992-11-10 2000-04-19 李泽琳 抗aids病毒的药物组合物
CN1105238A (zh) 1992-11-10 1995-07-19 中国预防医学科学院病毒学研究所 抗aids病毒的药物组合物
WO1995003311A1 (en) 1993-07-19 1995-02-02 Xuande Luo Qinghaosu derivatives against aids
US5409938A (en) * 1994-02-14 1995-04-25 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof
US5639761A (en) * 1994-02-14 1997-06-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US5677468A (en) * 1995-06-29 1997-10-14 Hauser, Inc. Artemisinin dimer compounds having anticancer activity
US6160004A (en) * 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
US6297272B1 (en) * 1999-01-12 2001-10-02 Hauser, Inc. Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same
AU2074201A (en) * 1999-12-08 2001-06-18 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
CA2395016C (en) 1999-12-30 2009-04-14 Henderson Morley Research And Development Limited Treatment of dna viral infections
EP1242096B1 (de) 1999-12-30 2005-10-12 Henderson Morley Research and Development Limited Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
GB0005382D0 (en) 2000-03-06 2000-04-26 Henderson Morley Res & Dev Ltd Pharmaceutical composition
DE60139134D1 (de) 2000-09-21 2009-08-13 Henderson Morley Res & Dev Ltd Diuretikum oder sulfonylharnstoff zur benutzung in antiviraler behandlung
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
US20040115651A1 (en) * 2002-12-12 2004-06-17 Isis Pharmaceuticals Inc. Modulation of BUB3 expression
CA2488347A1 (en) * 2002-06-06 2003-12-18 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
US7842719B2 (en) 2002-10-31 2010-11-30 Kemin Foods, L.C. Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
DE602004029651D1 (de) * 2003-02-12 2010-12-02 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
US20100178364A1 (en) * 2009-01-12 2010-07-15 Hanan Polansky Dietary supplements against latent foreign DNA

Also Published As

Publication number Publication date
US12128024B2 (en) 2024-10-29
CN103393672A (zh) 2013-11-20
US20190269648A1 (en) 2019-09-05
MXPA05008527A (es) 2006-03-08
DE602004029651D1 (de) 2010-12-02
US20120010278A1 (en) 2012-01-12
HK1083314A1 (en) 2006-06-30
CA2515761A1 (en) 2004-08-26
US20210038565A1 (en) 2021-02-11
US20070142459A1 (en) 2007-06-21
EP1594491A1 (de) 2005-11-16
EP2305243A1 (de) 2011-04-06
CN1758905A (zh) 2006-04-12
ES2353384T3 (es) 2011-03-01
US8394849B2 (en) 2013-03-12
US8940787B2 (en) 2015-01-27
US7989491B2 (en) 2011-08-02
EP1594491B1 (de) 2010-10-20
WO2004071506A1 (en) 2004-08-26
EP3257509A1 (de) 2017-12-20
US20170246145A1 (en) 2017-08-31
US20150196530A1 (en) 2015-07-16
US20130296411A1 (en) 2013-11-07
CA2515761C (en) 2013-04-23

Similar Documents

Publication Publication Date Title
ATE485039T1 (de) Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
PH12019550229A1 (en) Newcastle disease viruses and uses thereof
EA200700243A1 (ru) Способы лечения гепатита с
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DK1450799T3 (da) Arylurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
AU2003265556A8 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
DK1368054T3 (da) Anvendelse af neurale trådproteiner til behandling af tumorer
NO20023486D0 (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE533486T1 (de) Verwendung von pyridonderivaten zur vorbeugung und behandlung von strahlungsbedingter lungenverletzung
AU2003234342A8 (en) Ablated slam-dependent entry
ATE545423T1 (de) Mittel zur behandlung von lungenkrebs
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
UA90477C2 (ru) Способ лечения гепатита с (варианты)
ATE386748T1 (de) Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
DE502004008294D1 (de) Neue makrocyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties